EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Diagnostic Criteria Used in i‐ PRF Trials for Articular Temporomandibular Disorders: A Scoping Review

Leonardo Brigido Metello Neves, Bernardo Correia Lima, Ricardo Grillo

Oral Diseases · 2026-11-10

DOI: 10.1111/odi.70564 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Objective Injectable platelet‐rich fibrin (i‐PRF) is increasingly used for articular temporomandibular disorders (TMD), but it is unclear whether randomised controlled trials (RCTs) report validated diagnostic criteria for participant enrolment. This scoping review maps the diagnostic instruments reported in i‐PRF RCTs for articular TMD. It does not assess whether diagnostic systems were applied correctly or the accuracy of diagnoses. Methods Following the JBI framework and PRISMA‐ScR, RCTs evaluating i‐PRF for articular TMD and reporting pain and/or maximum mouth opening were searched in six databases, without date or language restrictions, plus grey literature, trial registries and reference lists. Diagnostic approaches, sample characteristics, imaging, interventions, comparators, follow‐up and adverse events were charted. Results Thirteen RCTs were included. Three reported DC/TMD for enrolment, two from the same research group. Five reported Wilkes staging, three reported imaging without a clinical diagnostic system, and two reported no diagnostic criterion. No trial reported RDC/TMD. Conclusion Fewer than a quarter of i‐PRF RCTs reported enrolment using a currently validated diagnostic system. This methodological finding does not indicate whether i‐PRF is effective. Future trials should use DC/TMD and report diagnostic procedures in full.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →